SCYNEXIS Inc (SCYX) Expected to Post Earnings of -$0.37 Per Share
Wall Street analysts predict that SCYNEXIS Inc (NASDAQ:SCYX) will post ($0.37) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for SCYNEXIS’s earnings. SCYNEXIS posted earnings per share of ($0.52) in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.8%. The business is scheduled to issue its next earnings results on Monday, May 8th.
On average, analysts expect that SCYNEXIS will report full-year earnings of ($1.73) per share for the current year. For the next financial year, analysts expect that the business will post earnings of ($2.16) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for SCYNEXIS.
SCYX has been the topic of several recent research reports. Zacks Investment Research downgraded SCYNEXIS from a “hold” rating to a “sell” rating in a report on Wednesday, December 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of SCYNEXIS in a research note on Friday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of SCYNEXIS in a research note on Wednesday, February 22nd. Guggenheim reaffirmed a “buy” rating and set a $15.00 target price on shares of SCYNEXIS in a research note on Friday, March 3rd. Finally, Aegis initiated coverage on SCYNEXIS in a research note on Tuesday, January 31st. They issued a “buy” rating and a $7.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $10.56.
Shares of SCYNEXIS (NASDAQ:SCYX) traded down 2.31% during trading on Monday, reaching $2.54. The company had a trading volume of 131,486 shares. SCYNEXIS has a 52-week low of $1.74 and a 52-week high of $5.51. The firm has a 50-day moving average price of $2.72 and a 200-day moving average price of $3.33. The company’s market capitalization is $64.84 million.
An institutional investor recently bought a new position in SCYNEXIS stock. Perceptive Advisors LLC purchased a new position in SCYNEXIS Inc (NASDAQ:SCYX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 171,185 shares of the company’s stock, valued at approximately $546,000. Perceptive Advisors LLC owned approximately 0.71% of SCYNEXIS as of its most recent SEC filing. Hedge funds and other institutional investors own 47.81% of the company’s stock.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SCYNEXIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.